A bacterium that causes pneumonia is being redesigned to act as a ‘cell doctor’ that detects and treats disease from inside the human body.
The idea of using bugs as tiny drug couriers is not new: scientists have been engineering viruses to deliver medicines and fix genetic defects for some time.
However, the potential of viruses is limited because they have a small number of genes and because they do not have an active metabolism of their own and cannot respond to the environment or the host. This limits the scope for their engineering for certain medical purposes.
‘Viruses can only carry a limited amount of information,’ said Professor Luis Serrano at the Centre for Genomic Regulation in Barcelona, Spain. ‘They have genes but, unlike bacteria, they do not have a metabolism so they cannot respond to changes in a human cell.’
Using bacteria instead of viruses to deliver treatments to specific parts of the body would provide greater scope for fighting disease because they have more genes to tweak.
However, bacteria are also significantly more complex to work with. For a start, they typically have cell walls – making it difficult for them to communicate with target cells – and they often draw a strong immune response when implanted into humans.
Now, scientists believe they may have found a suitable candidate that has more genes than a virus but is capable of getting into cells to carry out medical missions – and it’s one that we’ve previously associated with disease.
Mycoplasma pneumoniae can cause bacterial pneumonia in humans, but also ticks many of the boxes required to become a cell doctor. ‘It has no cell wall, it does not cause major inflammation and it can be grown in the lab,’ explained Prof. Serrano, who studied the bug as part of the CELLDOCTOR project, funded by the EU's European Research Council (ERC).
M. pneumoniae is also a very small bacterium. It is roughly the size of a mitochondrion – the subcellular powerhouse that provides our cells with energy.
Because it is so small and can enter cells without triggering a major immune reaction, Prof. Serrano sees the bug’s potential as a medical tool. ‘We want to engineer bacteria that can get into the human organism, detect anomalies and repair them.’
Professor Luis Serrano, Centre for Genomic Regulation, Spain
‘We want to engineer bacteria that can get into the human organism, detect anomalies and repair them.’
‘We want to engineer a vehicle that can get into the human organism, detect anomalies and repair them,’ he said. ‘It could live inside human cells like a parasite capable of improving health.’
Once inside the target cell, the bacterium would blend in with the other structures already there. But unlike the cell’s other subcellular furniture, the engineered M. pneumoniae bacterium would produce and secrete drugs that a patient needs, or proteins capable of correcting a genetic disease.
It would not cause disease itself because the researchers have genetically engineered the pneumoniae bacterium to ensure that it is not infectious.
Through the CELLDOCTOR project, Prof. Serrano focused on understanding what makes the bacterium tick before exploring its capacity for delivering drugs, vaccines and genes.
By understanding its genetics and biochemistry, the Barcelona-based researchers developed a deeper understanding of the bug – so that they could redesign a simple organism that would act like a living pill.
Thanks to additional ERC funding, Prof. Serrano was able to take this work one step further and look at specific uses of M. pneumoniae for treating lung and genital tract diseases in a project called MICO PLUNG.
‘Our initial work was pointing towards medical applications for M. pneumoniae and this… project was a chance to direct our efforts towards more clinically applied research,’ he explained.
The bacterium is known to live in lung tissue, so researchers are working on how genetically engineered versions of the bug could deliver therapeutic proteins that could fight against infectious respiratory disorders.
The team also see potential for bacteria to be used as vaccines, deliberately training the immune system to fight unwelcome viruses and bacteria.
Research in this area may change the way we think about bacteria such as M. pneumoniae by turning an old foe into a valuable ally.
Disease-fighting with microbes
Professor Martijn Nawijn, an immunologist at the University of Groningen in the Netherlands, tells Horizon about his quest to map every cell in a healthy human lung. He says this work should help to understand more about the causes of lung disease - which is comparatively understudied - and should lead to new therapies in the next 15 to 20 years.
There was one science story that dominated 2020 and coronavirus is likely to remain a dominant theme in 2021. But from vaccine rollout to lessons for future pandemics and – that other big challenge that we’re facing – climate change, how will the year in science play out? We asked a selection of our interviewees about lessons from 2020 and what needs to happen in their fields in the coming year.
In the summer of 2014 a strange building began to take shape just outside MoMA PS1, a contemporary art centre in New York City. It looked like someone had started building an igloo and then got carried away, so that the ice-white bricks rose into huge towers. It was a captivating sight, but the truly impressive thing about this building was not so much its looks but the fact that it had been grown.
Bilingual people can effortlessly switch between languages during everyday interactions. But beyond its usefulness in communication, being bilingual could affect how the brain works and enhance certain abilities. Studies into this could inform techniques for learning languages and other skills.
Live mycelium networks, capable of information processing, could be used as building materials.
Researchers are investigating whether bilingualism enhances certain cognitive abilities.
Dr Kate Rychert studies ocean plate structures.